State Street Corp Has $64.67 Million Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)

State Street Corp cut its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 8.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,113,590 shares of the company's stock after selling 107,786 shares during the period. State Street Corp owned approximately 2.75% of Keros Therapeutics worth $64,666,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. KBC Group NV grew its stake in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. purchased a new stake in Keros Therapeutics in the 3rd quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the 2nd quarter worth approximately $128,000. Finally, LMR Partners LLP purchased a new position in Keros Therapeutics during the third quarter valued at $213,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KROS. Oppenheimer reduced their target price on Keros Therapeutics from $102.00 to $63.00 and set an "outperform" rating on the stock in a report on Monday. Wells Fargo & Company upped their price objective on Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Cantor Fitzgerald reissued an "overweight" rating on shares of Keros Therapeutics in a report on Friday, November 22nd. William Blair lowered shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Thursday, December 12th. Finally, BTIG Research lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $81.33.

Keros Therapeutics Trading Down 1.2 %

Shares of Keros Therapeutics stock traded down $0.21 during mid-day trading on Thursday, reaching $16.92. 1,701,674 shares of the stock were exchanged, compared to its average volume of 483,350. The firm has a 50-day simple moving average of $56.64 and a 200 day simple moving average of $52.06. The company has a market cap of $685.38 million, a price-to-earnings ratio of -3.25 and a beta of 1.20. Keros Therapeutics, Inc. has a fifty-two week low of $15.67 and a fifty-two week high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million during the quarter. During the same quarter in the prior year, the company earned ($1.33) earnings per share. The company's quarterly revenue was up 4750.0% compared to the same quarter last year. On average, research analysts predict that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.